CA3206708A1 - Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis - Google Patents

Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis Download PDF

Info

Publication number
CA3206708A1
CA3206708A1 CA3206708A CA3206708A CA3206708A1 CA 3206708 A1 CA3206708 A1 CA 3206708A1 CA 3206708 A CA3206708 A CA 3206708A CA 3206708 A CA3206708 A CA 3206708A CA 3206708 A1 CA3206708 A1 CA 3206708A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
formula
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206708A
Other languages
English (en)
French (fr)
Inventor
Ida ARONCHIK
Roxxana Valeria BELTRAN VALENCIA
Maria Soraya Carrancio Anton
Henry H. Chang
Shodeinde COKER
Sharmila Das
Ellen Hope Filvaroff
Carla GUARINOS MARHUENDA
Bishoy HANNA
Yu Liu
Zariana NIKOLOVA
Oriana ESPOSITO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CA3206708A1 publication Critical patent/CA3206708A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
CA3206708A 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis Pending CA3206708A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21382163 2021-02-25
EP21382163.0 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US63/232,866 2021-08-13
US202263297098P 2022-01-06 2022-01-06
US63/297,098 2022-01-06
PCT/US2022/017678 WO2022182857A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Publications (1)

Publication Number Publication Date
CA3206708A1 true CA3206708A1 (en) 2022-09-01

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206708A Pending CA3206708A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Country Status (12)

Country Link
US (2) US12357621B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297750A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507938A (cg-RX-API-DMAC7.html)
KR (1) KR20230148208A (cg-RX-API-DMAC7.html)
AU (1) AU2022227673B2 (cg-RX-API-DMAC7.html)
CA (1) CA3206708A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002497A1 (cg-RX-API-DMAC7.html)
IL (1) IL304697A (cg-RX-API-DMAC7.html)
MX (1) MX2023009858A (cg-RX-API-DMAC7.html)
TW (1) TW202302095A (cg-RX-API-DMAC7.html)
WO (1) WO2022182857A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307538B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP4351560A4 (en) 2021-06-08 2025-06-04 The Regents of the University of California ANTI-CANCER COMPOUNDS
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
DK3908281T3 (da) * 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
IL304697A (en) 2023-09-01
TW202302095A (zh) 2023-01-16
US12357621B2 (en) 2025-07-15
AU2022227673A9 (en) 2024-09-19
JP2024507938A (ja) 2024-02-21
WO2022182857A1 (en) 2022-09-01
KR20230148208A (ko) 2023-10-24
AU2022227673B2 (en) 2026-06-04
MX2023009858A (es) 2023-09-12
ZA202307538B (en) 2026-01-28
EP4297750A1 (en) 2024-01-03
CL2023002497A1 (es) 2024-01-12
AU2022227673A1 (en) 2023-08-17
US20250367174A1 (en) 2025-12-04
US20220265617A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20250367174A1 (en) Bet inhibitors as a treatment for myelofibrosis
EP1261322B1 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2023515817A (ja) ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
JP2024012493A (ja) 消化管間質腫瘍の治療のための併用療法
CA2525366A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20090312290A1 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
US10576050B2 (en) Methods and compositions for treatment of cancer
US20150051236A1 (en) Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia
EA050366B1 (ru) Применение ингибиторов bet отдельно или в комбинации с федратинибом или с руксолитинибом для лечения гематологического злокачественного новообразования, такого как миелофиброз
WO2023204259A1 (ja) がんの治療又は予防用医薬
US20250381181A1 (en) Cancer treatment agent including malt1 inhibiting drug as active ingredient
CN117615759A (zh) Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途
AU2024359133A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
EP1441717B1 (en) Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
CN101267837B (zh) 用于治疗系统性肥大细胞增生症的组合物
EP1391203A1 (en) Antitumor agents
WO2006121919A2 (en) Methods of treating obsessive compulsive disorder
US20090176759A1 (en) Leukemic stem cell ablation
WO2025056055A1 (zh) 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260105

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260223

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260309

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260309